US 12,390,498 B2
Treatment of clostridium difficile infection
Jessica Schneider, Cambridge, MA (US); Yun-Gi Kim, Watertown, MA (US); Bernat Olle, Cambridge, MA (US); Shilpa Reddy, Watertown, MA (US); Jason Norman, North Weymouth, MA (US); and Juan Patarroyo, Lexington, MA (US)
Assigned to Vedanta Biosciences, Inc., Cambridge, MA (US)
Filed by Vedanta Biosciences, Inc., Cambridge, MA (US)
Filed on May 31, 2023, as Appl. No. 18/326,511.
Application 18/326,511 is a continuation of application No. 16/702,659, filed on Dec. 4, 2019, granted, now 11,701,396.
Application 16/702,659 is a continuation of application No. 16/423,487, filed on May 28, 2019, granted, now 10,555,980.
Application 16/423,487 is a continuation of application No. 16/157,640, filed on Oct. 11, 2018, granted, now 10,456,431.
Application 16/157,640 is a continuation of application No. 15/993,037, filed on May 30, 2018, granted, now 10,350,250.
Application 15/993,037 is a continuation of application No. 15/630,088, filed on Jun. 22, 2017, granted, now 9,999,641.
Application 15/630,088 is a continuation of application No. PCT/US2017/037498, filed on Jun. 14, 2017.
Claims priority of provisional application 62/349,914, filed on Jun. 14, 2016.
Prior Publication US 2024/0123000 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A23L 5/00 (2016.01); A23L 33/135 (2016.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 35/74 (2015.01); A61K 35/742 (2015.01); A61K 38/14 (2006.01); C12N 1/20 (2006.01); A23K 10/18 (2016.01); A23K 50/30 (2016.01)
CPC A61K 35/747 (2013.01) [A23L 5/00 (2016.08); A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 35/74 (2013.01); A61K 35/742 (2013.01); A61K 38/14 (2013.01); C12N 1/20 (2013.01); A23K 10/18 (2016.05); A23K 50/30 (2016.05); A61K 9/0031 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising a purified bacterial mixture, wherein the purified bacterial mixture consists of 7 to 10 bacterial strains, wherein the purified bacterial mixture comprises at least 7 of:
(i) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 157;
(ii) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 129;
(iii) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 132;
(iv) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 137;
(v) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 124;
(vi) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 141;
(vii) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 146; and
(viii) a bacterial strain comprising a 16S rDNA sequence having at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 152,
wherein the bacterial strains are lyophilized.